We are involved in various claims and legal proceedings of a nature considered ordinary course in our business, including those described under the heading “Legal Proceedings” in our 2025 Form 10-K and our Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2026. Most of the issues raised by these claims are highly complex and subject to substantial uncertainties. For a description of risks relating to these and other legal proceedings we face, see Part I, Item 1A., “Risk Factors,” of our 2025 Form 10-K, including the discussion under the headings entitled “Risks related to our intellectual property” and “Risks related to the manufacturing of our commercial products and product candidates.” The outcome of any such proceedings, regardless of the merits, is inherently uncertain; therefore, assessing the likelihood of loss and any estimated damages is difficult and subject to considerable judgment. Sanofi Patent Litigation In July 2026, Translate Bio, Inc., Translate Bio MA, Inc., Sanofi Vaccines US, Inc., and VaxServe, Inc. (all subsidiaries of Sanofi SA), filed a complaint against us in the U.S. District Court for the District of New Jersey asserting that our manufacture and sale of our COVID and RSV vaccines infringe U.S. patents related to compositions and methods for mRNA delivery. The complaint seeks a judgment of infringement of the asserted patents and unspecified damages.